In last trading session, BioNTech SE (NASDAQ:BNTX) saw 836,131 shares changing hands. Company’s recent per share price level of $58.01 trading at -$1.2 or -2.04% at recent trade assigns it a market valuation of $13.26 Billion. That current price of BNTX’s stock is at a discount of -81% from its 52-week high price of $105 and is indicating a premium of 78.42% from its 52-week low price of $12.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.45 Million shares which gives us an average trading volume of 1.41 Million if we extend that period to 3-months.

For BioNTech SE (BNTX), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.4. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.25 in the current quarter.

BioNTech SE (NASDAQ:BNTX) trade information

In the face of being in the red today for losing -1.76%, in the last five days BNTX remained trading in the green while hitting it’s week-highest on Thursday, Jun 25 when the stock touched $59.92- price level, adding 1.32% to its value on the day. BioNTech SE’s shares saw a change of 74.53% in year-to-date performance and have moved 15.13% in past 5-day. BioNTech SE (NASDAQ:BNTX) showed a performance of 16.21% in past 30-days. Number of shares sold short was 3.06 Million shares which calculate 2.17 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $45.22 to the stock, which implies targetted prices is already lagging behind -22.05% to its current value. Analysts have been projecting $28 as a low price target for the stock while placing it at a high target of $63. It follows that stock’s current price would jump +8.6% in reaching the projected high whereas dropping to the targeted low would mean a loss of -51.73% for stock’s current value.

BioNTech SE (BNTX) estimates and forecasts

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $28.3 Million for the same. And 6 analysts are in estimates of company making revenue of $41.17 Million in the next quarter that will end in June 01, 2020.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -300.5% while estimates for its earnings growth in next 5 years are of 0%

BioNTech SE (NASDAQ:BNTX)’s Major holders

Insiders are in possession of 1.26% of company’s total shares while institution are holding 4.15% percent of that, with stock having share float percentage of 4.2%. Investors also watch the number of corporate investors in a company very closely, which is 36 institutions for BioNTech SE that are currently holding shares of the company. Primecap Management Company is the top institutional holder at BNTX for having 2.61 Million shares of worth $152.55 Million. And as of March 30, 2020, it was holding 19.79% of the company’s outstanding shares.

The second largest institutional holder is Artal Group S.A., which was holding about 2.23 Million shares on March 30, 2020. The number of shares represents firm’s hold over 16.88% of outstanding shares, having a total worth of $130.12 Million.

On the other hand, Vanguard Horizon Fund-Capital Opportunity Portfolio and Primecap Odyssey Aggressive Growth Fund are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 1147783 shares of worth $67.03 Million or 8.7% of the total outstanding shares. The later fund manager was in possession of 945.78 Thousand shares on December 30, 2019, making its stake of worth around $32.04 Million in the company or a holder of 7.16% of company’s stock.